Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets

Thrombosis and Haemostasis

Volumn 103, Issue 3, 2010, Pages 545-555

  Munuswamy Ramanujam, Ganesh ^a,b,c   Dai, Erbin ^a,b   Liu, Liying ^a,b   Shnabel, Mira ^b,c   Sun, Yun Ming ^b,c,d   Bartee, Mee ^a   Lomas, David A ^e   Lucas, Alexandra R ^a,b,c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d Viron Therapeutics Inc   (Canada)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Atherosclerosis; Neuroserpin; Serpin; T helper lymphocyte; Transplant vasculopathy

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 4; NEUROSERPIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLASMINOGEN ACTIVATOR INHIBITOR 3; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

ALLOGRAFT; ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASCITES; BRAIN INFARCTION; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL POPULATION; CONTROLLED STUDY; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; HELPER CELL; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; VASCULAR DISEASE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTA; AORTIC DISEASES; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; NEUROPEPTIDES; SERPINS; T-LYMPHOCYTES, HELPER-INDUCER; TRANSPLANTATION; VASCULAR DISEASES;

EID: 77749289262     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-07-0441     Document Type: Article

References (50)

1. Weiss MJ, Madsen JC, Rosengard BR, et al. Mechanisms of chronic rejection in cardiothoracic transplantation. Front Biosci 2008; 13: 2980-2988.
2. Belperio JA, Weigt SS, Fishbein MC, et al. Chronic lung allograft rejection: mechanisms and therapy. Proc Am Thorac Soc 2009; 6: 108-121.
3. Cornell LD, Smith RN, Colvin RB. Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev Pathol 2008; 3: 189-220.
4. Weis M, von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation 1997; 96: 2069-2077.
5. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signalling: a vascular biologist's view. Thromb Haemost 2007; 97: 336-342.
6. Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 2004; 25: 450-455.
7. Diebold I, Kraicun D, Bonello S, et al. The 'PAI-1 paradox' in vascular remodelling. Thromb Haemost 2008; 100: 984-991.
8. Qian HS, Gu JM, Liu P, et al. Overexpression of PAI-1 prevents the development of abdominal aortic aneurysm in mice. Gene Ther 2008; 15: 224-232.
9. Nicholl SM, Roztocil E, Davies MG. Plasminogen activator system and vascular disease. Curr Vasc Pharmacol 2006; 4: 101-116.
10. Yepes M, Lawrence DA. Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system? Trends Cardiovasc Med 2004; 14: 173-180.
11. Miranda E, Lomas DA. Neuroserpin: a serpin to think about. Cell Mol Life Sci 2006; 63: 709-722.
12. Osterwalder T, Cinelli P, Baici A, et al. The axonally secreted serine proteinase inhibitor, neuroserpin, inhibits plasminogen activators and plasmin but not thrombin. J Biol Chem 1998; 273: 2312-2321.
13. Cinelli P, Madani R, Tsuzuki N, et al. Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol Cell Neurosci 2001; 18: 443-457.
14. Simonin Y, Charron Y, Sonderegger P, et al. An inhibitor of serine proteases, neuroserpin, acts as a neuroprotective agent in a mouse model of neurodegenerative disease. J Neurosci 2006; 26: 10614-10619.
15. Nash P, Whitty A, Handwerker J, et al. Inhibitory specificity of the anti-inflammatory myxoma virus serpin, SERP-1. J Biol Chem 1998; 33: 20982-20991.
16. Dai E, Guan H, Liu L, et al. Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury. J Biol Chem 2003; 278: 18563-18572.
17. Bot I, von der Thüsen JH, Donners MM, et al. Serine protease inhibitor Serp-1 strongly impairs atherosclerotic lesion formation and induces a stable plaque phenotype in ApoE-/-mice. Circ Res 2003; 93: 464-471.
18. Bédard EL, Jiang J, Arp J, et al. Prevention of chronic renal allograft rejection by SERP-1 protein. Transplantation 2006; 81: 908-914.
19. Hausen B, Boeke K, Berry GJ, et al.. Viral serine proteinase inhibitor (SERP-1) effectively decreases the incidence of graft vasculopathy in heterotopic heart allografts. Transplantation 2001; 72: 364-368.
20. Jiang J, Arp J, Kubelik D, et al. Induction of indefinite cardiac allograft survival correlates with toll-like receptor 2 and 4 downregulation after serine protease inhibitor-1 (Serp-1) treatment. Transplantation 2007; 84: 1158-1167.
21. Wang H, Jiang J, McFadden G, et al. Serp-1, a viral anti-inflammatory serpin, attenuates acute xenograft rejection in a rat-to-mouse cardiac transplantation model. Xenotransplant 2003; 5: 506.
22. Lucas A, Dai E, Liu L, et al. Transplant vasculopathy: viral anti-inflammatory serpin regulation of atherogenesis. J Heart Lung Transplant 2000; 19: 1029-1038.
23. Richardson J, Viswanathan K, Lucas A. Serpins, the vasculature, and viral therapeutics. Front Biosci 2006; 1: 1042-1056.
24. Zhou X. CD4+ T cells in atherosclerosis. Biomed Pharmacother 2003; 57: 287-291.
25. Zhou X, Robertson AK, Hjerpe C, et al. Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 864-870.
26. Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol 2006; 26: 2421-2432.
27. Buono C, Binder CJ, Stavrakis G, et al.. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci USA 2005; 102: 1596-1601.
28. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008; 79: 360-376.
29. Huber SA, Sakkinen P, David C, et al. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation 2001; 103: 2610-2616.
30. Tesmer LA, Lundy SK, Sarkar S. Th17 cells in human disease. Immunol Rev 2008; 223: 87-11 3.
31. Afzali B, Lombardi G, Lechler RI, et al. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148: 32-46.
32. Cheng X, Yu X, Ding YJ, et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008; 127: 89-97.
33. Le Luduec JB, Condamine T, Louvet C, et al. An immunomodulatory role for follistatin-like 1 in heart allograft transplantation. Am J Transplant 2008; 8: 2297-2306.
34. Hsieh HG, Loong CC, Lui WY, et al. IL-17 expression as a possible predictive parameter for subclinical renal allograft rejection. Transpl Int 2001; 14: 287-298.
35. Lucas A, Liu L, Macen J, et al. Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty. Circulation 1996; 94: 2890-2900.
36. Nash P, Barry M, Seet BT, et al. Post-translational modification of the myxomavirus anti-inflammatory serpin SERP-1 by a virally encoded sialyltransferase. Biochem J 2000; 347: 375-382.
37. Dai E, Viswanathan K, Sun YM, et al. Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses. J Biol Chem 2006; 281: 8041-8050.
38. Viswanathan K, Liu L, Vaziri S, et al. Myxoma viral serpin, Serp-1, a unique interceptor of coagulation and innate immune pathways. Thromb Haemost 2006; 95: 499-510.
39. Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 2008; 38: 2636-2649.
40. Iwakura Y, Nakae S, Saijo S, et al. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008; 226: 57-79.
41. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol 2005; 98: 1154-1162.
42. Levi M, Schouten M, van der Poll T. Sepsis, Coagulation, and Antithrombin: Old Lessons and New Insights. Semin Thromb Hemost 2008; 34: 742-746
43. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008; 8: 802-815.
44. Szabo SJ, Sullivan BM, Stemmann C, et al. Distinct effects of T-bet in Th1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science 2002; 295: 338-342.
45. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89: 587-596.
46. Layh-Schmitt G, Colbert RA. The interleukin-23/interleukin-17 axis in spondyloarthritis. Curr Opin Rheumatol 2008; 20: 392-397.
47. Daftarian PM, Kumar A, Kryworuchko M, et al. IL-10 production is enhanced in human T cells by IL-12 and IL-6 and in monocytes by tumor necrosis factoralpha. J Immunol 1996; 157: 12-20.
48. Murata N, Los DA. Membrane fluidity and temperature perception. Plant Physiol 1997; 115: 875-879.
49. Vigh L, Maresca B, Harwood JL. Does the membrane's physical state control the expression of heat shock and other genes? Trends Biochem Sci 1998; 23: 369-374.
50. Zalai CV, Kolodziejczyk MD, Pilarski L, et al. Increased circulating monocyte activation in patients with unstable coronary syndromes. J Am Coll Cardiol 2001; 38: 1340-1348.